Enicar Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 28-06-2024
- Paid Up Capital ₹ 0.90 M
as on 28-06-2024
- Company Age 30 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 22.66 Cr
as on 28-06-2024
- Satisfied Charges ₹ 24.64 Cr
as on 28-06-2024
- Revenue 19.47%
(FY 2022)
- Profit -32.62%
(FY 2022)
- Ebitda 6.16%
(FY 2022)
- Net Worth 10.12%
(FY 2022)
- Total Assets 44.36%
(FY 2022)
About Enicar Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.90 M.
The company currently has active open charges totaling ₹22.66 Cr. The company has closed loans amounting to ₹24.64 Cr, as per Ministry of Corporate Affairs (MCA) records.
Swarali Save, Sharmila Save, and Milind Save serve as directors at the Company.
- CIN/LLPIN
U24230MH1994PTC079450
- Company No.
079450
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jul 1994
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Enicar Pharmaceuticals Private Limited offer?
Enicar Pharmaceuticals Private Limited offers a wide range of products and services, including Cough Syrup, Multivitamin Syrup & Drops, Vitamin B Complex Syrup, Nutraceuticals & Dietary Supplements, Nutritional Supplements, Veterinary Medicines, Fertilizer, Amino Acids.
Who are the key members and board of directors at Enicar Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Swarali Save  | Director | 05-Oct-2011 | Current |
| Sharmila Save | Director | 06-Jul-1994 | Current |
| Milind Save | Director | 06-Jul-1994 | Current |
Financial Performance and Corporate Structure Insights of Enicar Pharmaceuticals.
Enicar Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 19.47% increase. The company also saw a substantial fall in profitability, with a 32.62% decrease in profit. The company's net worth Soared by an impressive increase of 10.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Enicar Pharmaceuticals?
In 2022, Enicar Pharmaceuticals had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Goverdhan Graphics Corrugator Private LimitedActive 3 years 2 months
Swarali Save is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 19 Aug 2020 | ₹3.54 Cr | Open |
Axis Bank Limited Creation Date: 29 Jan 2018 | ₹19.08 Cr | Open |
The Saraswat Co-Operative Bank Ltd. Creation Date: 11 Dec 2003 | ₹0.44 M | Open |
How Many Employees Work at Enicar Pharmaceuticals?
Enicar Pharmaceuticals has a workforce of 216 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Enicar Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Enicar Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
